Has FDA Reached A "New Normal"? Parexel Thinks Lower Review Metrics May Be Here To Stay, Though FDA Hopes To Improve
Executive Summary
Shortly after the third anniversary of the FDA Amendments Act, the repercussions of FDA's new authorities and responsibilities for drug review performance are becoming clearer.
You may also be interested in...
FDA May Be Catching Up With FDAAA Workload, Latest Performance Data Suggests
Preliminary FDA data indicate the agency may be catching up with the workload imposed by the FDA Amendments Act, with the agency reporting it could meet 10 of 12 review performance goals for NDAs and BLAs submitted in fiscal 2009.
FDA May Be Catching Up With FDAAA Workload, Latest Performance Data Suggests
Preliminary FDA data indicate the agency may be catching up with the workload imposed by the FDA Amendments Act, with the agency reporting it could meet 10 of 12 review performance goals for NDAs and BLAs submitted in fiscal 2009.
The Good Old Days: FDA's Jenkins Instructs Reviewers To Meet Original User Fee Review Time Standard
After an almost two-year hiatus from strict adherence to the review timeframes set forth in the Prescription Drugs User Fee Act, Office of New Drugs Director John Jenkins has told the drug review staff that, once again, they should strive to meet the user fee deadlines